1681 related articles for article (PubMed ID: 23348503)
1. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
2. Highly recurrent TERT promoter mutations in human melanoma.
Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
[TBL] [Abstract][Full Text] [Related]
3. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations in cancer development.
Heidenreich B; Rachakonda PS; Hemminki K; Kumar R
Curr Opin Genet Dev; 2014 Feb; 24():30-7. PubMed ID: 24657534
[TBL] [Abstract][Full Text] [Related]
6. [Tert promoter mutations in melanoma: not only the MAP-kinase pathway].
Dereure O
Ann Dermatol Venereol; 2013; 140(6-7):487-8. PubMed ID: 23773757
[No Abstract] [Full Text] [Related]
7. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
8. EWS/ETS fusions activate telomerase in Ewing's tumors.
Takahashi A; Higashino F; Aoyagi M; Yoshida K; Itoh M; Kyo S; Ohno T; Taira T; Ariga H; Nakajima K; Hatta M; Kobayashi M; Sano H; Kohgo T; Shindoh M
Cancer Res; 2003 Dec; 63(23):8338-44. PubMed ID: 14678994
[TBL] [Abstract][Full Text] [Related]
9. Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells.
Shukla AA; Jain M; Chauhan SS
FEBS J; 2010 Apr; 277(8):1861-75. PubMed ID: 20236318
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
11. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
12. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
[TBL] [Abstract][Full Text] [Related]
13. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the promoter for the alpha3 integrin gene in various tumor cell lines: roles of the Ets- and Sp-family of transcription factors.
Katabami K; Kato T; Sano R; Ogura M; Mizuno H; Itoh S; Tsuji T
J Cell Biochem; 2006 Feb; 97(3):530-43. PubMed ID: 16211576
[TBL] [Abstract][Full Text] [Related]
15. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway.
Maida Y; Kyo S; Kanaya T; Wang Z; Yatabe N; Tanaka M; Nakamura M; Ohmichi M; Gotoh N; Murakami S; Inoue M
Oncogene; 2002 Jun; 21(26):4071-9. PubMed ID: 12037663
[TBL] [Abstract][Full Text] [Related]
16. Ternary complex factors SAP-1 and Elk-1, but not net, are functionally equivalent in thymocyte development.
Costello P; Nicolas R; Willoughby J; Wasylyk B; Nordheim A; Treisman R
J Immunol; 2010 Jul; 185(2):1082-92. PubMed ID: 20554967
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
18. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells.
Chang JT; Yang HT; Wang TC; Cheng AJ
Mol Carcinog; 2005 Nov; 44(3):183-92. PubMed ID: 16010690
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells.
Ma H; Urquidi V; Wong J; Kleeman J; Goodison S
Mol Cancer Res; 2003 Aug; 1(10):739-46. PubMed ID: 12939399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
